Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

Core Insights - Aquestive Therapeutics, Inc. is presenting a crossover study of its product candidate Libervant™ (diazepam) Buccal Film for treating epilepsy in children aged two to five at the 76th Annual Meeting of the American Academy of Neurology [1][2] - Libervant is designed as an oral alternative to existing device-based treatments for seizure clusters in pediatric patients, aiming to improve patient well-being [2][3] - The FDA has granted tentative approval for Libervant for patients aged 12 and older, with a New Drug Application (NDA) for younger patients currently under review, targeting a PDUFA action date of April 28, 2024 [3][4] Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, with a pipeline aimed at treating central nervous system diseases and severe allergic reactions [4] - The company has five commercialized products and collaborates with other pharmaceutical companies to develop new molecules using proprietary technologies [4]